22/09/2026 Amgen reported positive Phase 3 results for dazodalibep in moderate-to-severe systemic sjögren's disease AbbVie’s RINVOQ® received EU approval for children with active pJIA Amgen reported positive Phase 3 results for dazodalibep in moderate-to-severe systemic sjögren's disease (Ref) Amgen’s Ph3 OASIZ 301 trial of dazodalibep (CD40L antagonist) met its primary endpoint, demonstrating statistically significant and clinically meaningful improvement in systemic disease

27/08/2026 AbbVie submitted a regulatory application to the EMA for SC induction dosing of risankizumab in adults with moderately to severely active CD TEZSPIRE® demonstrated positive phase 3 results in eosinophilic esophagitis across both co-primary and all key secondary endpoints Argenx completed the acquisition of Forte Biosciences Priovant announced the US FDA approval of brepocitinib for adults with dermatomyositis AbbVie submitted a regulatory application to the EMA for

06/04/2026 Tenvie Therapeutics announced dosing of first subject in Phase 1 trial of TNV262 Amgen announced topline results from Phase 3 teprotumumab in active TED Tenvie Therapeutics announced dosing of first subject in Phase 1 trial of TNV262 ( Ref ) Tenvie Therapeutics announced the first subject dosed in a Phase 1 clinical study evaluating TNV262 (a fully CNS-penetrant small molecule inhibitor targeting NLRP3) for the treatment of cardiometabolic diseases, including obesi

12/02/2026 The European Commission approved inebilizumab for the treatment of generalized myasthenia gravis The European Commission approved inebilizumab for the treatment of generalized myasthenia gravis ( Ref ) The European Commission approved Amgen’s Uplizna®(inebilizumab; anti-CD19 mAb) as an add-on treatment to standard therapy for adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (M